New evidence and guideline recommendations strongly support educating patients about their acute and chronic pain as well as the non-opioid alternatives available for pain management. However, in recent surveying, prior to exposure to CME Outfitters education, 45% of clinicians shared this information with their patients less than 50% of the time.
This podcast is the second episode in a CMEOCast series and focuses on making informative treatment decisions for pain management in order to change habits and improve outcomes. As part of that process is to educate patients in order to manage their expectations, it features expert faculty discussing strategies on how to best assess patients for misuse and communicate necessary information with patients.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Johnson & Johnson, administered by Johnson & Johnson.
Physicians, orthopedic surgeons, physician assistants (PAs), nurse practitioners (NPs), and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Gebke has no disclosures to report.
Dr. Mir has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.